Image

Mechanisms Underlying Individual Variations of Taste and Smell in Obesity

Mechanisms Underlying Individual Variations of Taste and Smell in Obesity

Recruiting
18-65 years
All
Phase N/A

Powered by AI

Overview

Background

Changes to the sense of taste or smell can change eating behavior. This may contribute to obesity. Researchers want to see how taste and smell perceptions that affect food choices may differ between people with obesity and without obesity.

Objective

To understand the role that senses of taste and smell play in food intake.

Eligibility

Adults ages 18-65 with obesity and without obesity

Design

Participants will be screened with a medical history and physical exam. They will have a neurological and sensory exam. They will give blood and urine samples. They will be checked for previous SARS-CoV-2 infection. They will complete questionnaires about their eating habits, alcohol use, and smoking history.

Participants will have 2 study visits.

Participants will give stool, urine, blood, hair, nasal, and saliva samples. These samples will be used for gene testing.

Participants will have their weight, height, and hip and waist circumference measured. They will have an imaging scan that measures body composition.

Participants will complete questionnaires about their health, eating habits, and food preferences.

Participants will have taste tests and smell tests. They will have sensory tests to assess their response to stimuli.

Participants will have a dietary assessment. They will complete a food diary and a diet history questionnaire.

Participants will get a meal to eat. Data will be collected about their experience.

Participants will complete a sleep diary and wear a watch to measure their activity....

Description

Study Description:

This study involves comparison of taste and smell measures between obese and non-obese individuals. Taste and smell perceptions will be assessed in terms of their influence in food intake and food choices. We hypothesize that obesity negatively affects taste and smell perception thus affecting eating behavior.

Objectives

Obesity is a major public health concern in America. An unhealthy diet is a recognized risk factor for the development of obesity. Public health efforts to modify eating behaviors have had limited success. Not only does an unhealthy diet contribute to obesity, but it can also lead to changes in gut microbiota that likely result in inflammation and changes in transcriptomic activity. Taste and smell perceptions, which can influence food choices and food consumption, may differ between obese and non-obese individuals. Currently, little is known about the underlying mechanisms causing variations in taste and smell systems in individuals with obesity, which limits the interventions currently available to address this critical issue. Findings from this study can be used to design more effective interventions for the prevention and treatment of obesity, to identify targets and strategies for countermeasures to prevent or improve obesity and its comorbidities, and to suggest ways to enhance dietary interventions. Moreover, findings will foster new lines of investigation for reducing risk of diet related conditions and for developing novel behavioral and pharmacological avenues of treatment and prevention. The proposed research is aligned with the overall mission of the National Institutes of Health to promote health and disease prevention. The findings from this study will ultimately lead to the development of personalized interventions for individuals with obesity and concurrent taste and smell alterations. Lastly, approaches included in this proposal are innovative and highly applicable to other complex health phenomena in which biological variations in inflammation and taste and smell perception impact an individual s health.

Endpoints

Primary Endpoint: The primary dependent measures for this study are taste and olfaction measures.

Secondary Endpoints: Secondary measures include inflammatory markers, exosomes, microbiota, gene expression, DNA methylation, biological measures and personal factors.

Eligibility

  • INCLUSION CRITERIA:
        In order to be eligible to participate in this study, an individual must meet all of the
        following criteria:
          -  Males and females between 18 to 65 years of age. Due to documented knowledge that
             taste and smell changes with age, we will limit the cohort within this age range.
          -  BMI between 18.5 and 29.9 kg/m^2 for healthy controls or between 30 and 39.9 kg/m^2
             for obese subjects
          -  Fasted plasma glucose levels between 68-126 mg/dl or per Clinical Center ranges, and
             hemoglobin A1C<6.5%
          -  Able to provide his/her own consent
          -  Able to understand the protocol, as shown by scoring a 6 out of 6 on a consent quiz
        EXCLUSION CRITERIA:
        An individual who meets any of the following criteria will be excluded from participation
        in this study:
          -  Because type-2 diabetic subjects have blunted taste responses, subjects with diagnosis
             of type II diabetes will be excluded.
          -  Hypoglycemic drug intake.
          -  Weight change of more than 15 pounds in the 6 months prior to screening
          -  Positive pregnancy test, currently pregnant or breastfeeding.
          -  Currently using any of the following medications: steroidal or nonsteroidal
             antiinflammatory medications, medications known to inhibit taste response (GLP1
             agonists), antiepileptic or antidepressant agents, glucocorticoids, or antibiotics.
          -  Received a diagnosis by a medical professional of morbid obesity, liver or renal
             disease.
          -  Individuals with current heavy drinking. Women who drink 4 drinks or more in one
             occasion and 7 drinks in a week. Men who drink 5 drinks or more in one occasion and
             more than 14 drinks a week.
          -  Use of tobacco products or illicit drugs (as determined by urine drug screen and/or
             history/physical exam) in the last 30 days.
          -  Currently have an uncontrolled medical disorder (i.e., gastrointestinal, endocrine,
             cardiac, psychiatric).
          -  Any self-reported history of chronic rhinitis, eating disorder (including binge
             eating), chronic upper respiratory infection, chronic allergic rhinitis, or nasal
             polyps in the last 6 months of screening, or current daily use of nasal sprays.
          -  Abnormal complete blood count (CBC): White Blood Cell Count < 4 or > 10 K/uL, Red
             Blood Cell Count < 4 or > 7 M/uL, Hemoglobin < 12 g/dL for females or < 13 g/dL for
             males or any clinical signs/symptoms that indicate iron deficiency anemia per
             clinician s judgment at screening [National Heart, Lung and Blood Institute (NHLBI)
             definition (Anemia - Iron-Deficiency Anemia, Diagnosis NHLBI, NIH)].
          -  Bariatric surgery within the last 12 months of screening.
          -  History of cancer (e.g., head and neck cancer) and/or history of cancer treatment
             (e.g., radiotherapy to the head and neck area or chemotherapy).
          -  Altered cranial nerves identified by neurological evaluation during physical exam
             (screening visit).
          -  Currently experiencing temporary change/loss of taste and/or smell.
          -  Persistent loss of taste and/or smell due to COVID-19 or other reasons.
          -  Unable to read and understand English. Since all self-report measures are in English
             only, participants need to be able to read and understand the English language.
          -  NIAAA employees/staff or subordinates/relatives/co-workers of NIAAA employees/staff or
             study investigators.

Study details
    Obesity

NCT04714892

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

19 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.